Description  Claims  Drawing  Cited references 

WO2004084365A   [0004] 
WO07084786A   [0005]  [0006]  [0006]  [0007]  [0017] 

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy   [0002] 
EGFR mutation and resistance of non-small cell lung cancer to gefitinib   [0002] 
Bcr-Abl point mutants isolated from patients with imatinib mesylate resistant chronic leukemia reamin sensitive to inhibitors of the Bcr-Abl chaperone heat shock protein 90   [0002] 
Acquired resistance to Imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation   [0002] 
The p110 alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation   [0003] 
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non small cell lung cancer cell lines   [0003] 
Allelic disruption obscures detection of a biologically significant resistance mutation in EGFR amplified lung cancer   [0003] 
Mendelsohn and Baselga; Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer   [0011] 
Epidermal Growth Factor Receptor Targeting in Cancer   [0011] 
EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy   [0011] 
EGFR targeting of solid tumors   [0011]